Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 139 participants.

Also called NCT02622113

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 139 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02622113
Other papers using this trial's data
  • Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus Diabetes, obesity & metabolism, 2018-04 DOI, PubMed 29110384, PMC5873413 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02622113. Allocation not applicable; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2019-03-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Canagliflozin (TA-7284)
Intervention (Drug)
Insulin
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02622113
Content hash
f2beae5691c1c06da1d018e9a323b0c931e94d1b78e827db3807a4ca94e208f9